Prostrakan's anal fissure pain drug refiled with US FDA
This article was originally published in Scrip
Executive Summary
The FDA has accepted Prostrakan's re-submission of Cellegesic (nitroglycerin) 0.4% ointment for moderate to severe pain associated with chronic anal fissures, three years after the agency issued an action letter for the troubled drug.